---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-25-000064"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:12:52.607432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M

## Summary
- Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.
- KLARITY Phase 2 trial for KIO-104 in retinal inflammation initiated; patent exclusivity extended to 2043.
- ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa initiated with validated functional vision endpoint.
- Option agreement with Senju for KIO-301 in Asia; potential deal value up to $110M plus royalties; $1.25M option fee received.
- R&D expense $2.6M offset by $1.7M Théa reimbursement; G&A down to $1.4M from $1.5M.

## SEC filing metadata
- accession: 0001372514-25-000064
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000064/0001372514-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000064/kprx-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-25-000064
- JSON: https://secwatch.observer/filing/0001372514-25-000064.json
- Plain text: https://secwatch.observer/filing/0001372514-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.